The ICER value of the vast majority of innovative drugs is higher than the threshold, and raising the threshold of medical insurance access indiscriminately is not conducive to stimulating the research and development of innovative drugs with high incremental value. Innovative drugs should be subdivided and policies should be differentiated. Some drugs cannot be sustained by medical insurance funds, however, compared with of similar drugs, they have higher incremental value, as a result, medical insurance and patients can share the drug costs.